Wordt geladen...
CYP2C9 Genotype and Pharmacodynamic Responses to Losartan in Patients with Primary and Secondary Kidney Diseases
Losartan is used for anti-proteinuric as well as blood pressure effects in chronic kidney disease (CKD). It is metabolized by cytochrome P450 2C9 to active E-3174. Single nucleotide polymorphisms in CYP2C9 that reduce catalytic activity could reduce clinical benefits. The study aims were to determin...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2009
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2901912/ https://ncbi.nlm.nih.gov/pubmed/19669737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00228-009-0707-7 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|